About: Identifying a Clinically Applicable Mutational Burden Threshold as a Potential Biomarker of Response to Immune Checkpoint Therapy in Solid Tumors

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Identifying a Clinically Applicable Mutational Burden Threshold as a Potential Biomarker of Response to Immune Checkpoint Therapy in Solid Tumors Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 07 December 2017

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована у 2017 (uk) artículu científicu espublizáu n'avientu de 2017 (ast) scientific article published on 07 December 2017 (en)
publication date	wds:Q57216049-EBC81C67-3FCD-4B7A-B991-CD9193B19D95
publication date	2017-12-07 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q57216049-32B7F432-15B7-4C59-B440-1E30627AE630
language of work or name	English
cites work	wds:Q57216049-0AF228A5-5038-432D-9FF6-EDDCBE69503B wds:Q57216049-102BC0B2-175B-4C2D-B619-DAF1D037E176 wds:Q57216049-2A6DE6B6-D5FE-4E8B-8AAB-5CE3C982240B wds:Q57216049-3C36E51A-8F00-4677-A920-1B2DF49B33FC wds:Q57216049-3DD2E4F1-865E-47D8-9B5D-3AAF92D85FD2 wds:Q57216049-4091D1B7-826D-4F83-8B2F-8DC0CE29D1B6 wds:Q57216049-48ACB060-82F8-482D-9964-F4C7DD05EA68 wds:Q57216049-4E6426D9-5C84-446B-B93B-D4E57445C606 wds:Q57216049-5064450A-4063-4E92-A193-81C56C392353 wds:Q57216049-51A9C23A-BC27-4E80-BD2E-503E97CB2220 wds:Q57216049-57236184-9093-4A1D-9CD8-09521B55543C wds:Q57216049-5B3ABE0A-8CCD-42F2-A39B-6D91988485F1 wds:Q57216049-5F1E0CB0-FE90-4F3F-9238-BF0837BAB802 wds:Q57216049-60CC83E7-C1FF-415A-A276-B38A3FE09348 wds:Q57216049-7215C305-7845-4A96-A2AA-D89DACDA8B85 wds:Q57216049-9469D3F0-3643-4C8B-9DDF-26957DF178FE wds:Q57216049-96EDA733-22C3-4DBE-A887-322BBD6EC8BA wds:Q57216049-97525670-4B77-4CBD-8297-3EE18F369247 wds:Q57216049-A3C6BF87-E042-408D-88D6-786B83D41C67 wds:Q57216049-AA4D7FCF-353F-4BC1-B675-3D04F5A5F2EE wds:Q57216049-AAA3B530-3FE0-4526-BF0D-8DD04646CC3D wds:Q57216049-B0CD67DD-59D6-46F8-BDA0-97EC976A5E0A wds:Q57216049-BCF4F7B5-C7B5-4D87-9504-CB2FD50B0ADC wds:Q57216049-C451A034-26A3-4901-AE7E-06AD6AF7129C wds:Q57216049-C46396D7-B7F1-49BA-91DD-C4168F1694C4 wds:Q57216049-C6B9AD4E-DE42-4A61-B23F-FFE5DFCA0EF7 wds:Q57216049-C7165C13-1569-49C6-A7BC-F98AFC67767E wds:Q57216049-C8E14DFE-3542-4776-AE31-EDC8F3595FA4 wds:Q57216049-CB0A4F8D-E812-4517-BF3F-FE211713FD5F wds:Q57216049-CF162C33-81DC-4035-8E27-97214896374C wds:Q57216049-D4751FA9-1804-4B05-A297-1C09C9189422 wds:Q57216049-DC5D4A0A-0C07-4A54-9E39-0A239081E07D wds:Q57216049-E55CF2C0-FD54-4059-A983-CF76CA3AF235 wds:Q57216049-E8DA7845-B29B-4776-B4FD-E357370423E5 wds:Q57216049-E9805E8B-5E88-4AF6-9E6B-445B4DEB2C9F wds:Q57216049-EAE4205D-901E-4326-8BBA-825C8FE9774B wds:Q57216049-F067797B-85FF-44D4-B286-14673E879926 wds:Q57216049-F1D40021-542A-4C96-8888-AE0F89022A9E wds:Q57216049-F4D515BA-A5DE-413F-921E-8B30468FCCAA wds:Q57216049-FBBCBEA5-A86E-4FFD-B27F-66DA13B0CF3C
cites work	Activin type II receptor restoration in ACVR2-deficient colon cancer cells induces transforming growth factor-beta response pathway genes. Inferring tumour purity and stromal and immune cell admixture from expression data Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses Mutational heterogeneity in cancer and the search for new cancer-associated genes Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma Regulatory T cells, tumour immunity and immunotherapy Towards the introduction of the 'Immunoscore' in the classification of malignant tumours Comprehensive molecular portraits of human breast tumours PD-1 blockade induces responses by inhibiting adaptive immune resistance An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency Structural representations of tumor-host relationships in mammary carcinoma; biologic and prognostic significance A genetic model for colorectal tumorigenesis Repeated observation of breast tumor subtypes in independent gene expression data sets Signatures of mutational processes in human cancer Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer Genetic basis for clinical response to CTLA-4 blockade in melanoma NK cells and cancer immunosurveillance. Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. Targeting natural killer cells in cancer immunotherapy Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected A specific spectrum of p53 mutations in lung cancer from smokers: review of mutations compiled in the IARC p53 database Landscape of somatic mutations in 560 breast cancer whole-genome sequences UV mutagenic photoproducts in Escherichia coli and human cells: a molecular genetics perspective on human skin cancer. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma Oncotator: cancer variant annotation tool Robust enumeration of cell subsets from tissue expression profiles Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade Opposite Effects of M1 and M2 Macrophage Subtypes on Lung Cancer Progression. Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer Innate immune signaling and regulation in cancer immunotherapy T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Understanding the origins of human cancer StrandAdvantage test for early-line and advanced-stage treatment decisions in solid tumors.
author name string	wds:Q57216049-0B22EADF-9C02-4354-9A37-F8B23634EC02 wds:Q57216049-0D1665E9-3FC7-4F16-96A1-AF4A1A82BE78 wds:Q57216049-2D1044BF-0DD5-4B69-950B-7BA99A14798C wds:Q57216049-3544C273-0959-4E82-AED4-37AB820011DA wds:Q57216049-459AB40A-1CD2-41BD-A97A-BB772C2E7754 wds:Q57216049-681C2697-DB95-43FC-ACCF-D13616632219 wds:Q57216049-6C05D8A1-D715-451E-B966-0B0CB12BAEFF wds:Q57216049-6D1A1617-5575-46A8-A9CF-03DB3DB49672 wds:Q57216049-6DC8FB9A-87AD-48BF-BA66-97DE239A63FC wds:Q57216049-80F61A23-E96E-4330-88DC-37DAB2284715 wds:Q57216049-8D493041-7236-47F3-A03F-A836F83B9757

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 172 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software